151 related articles for article (PubMed ID: 24121993)
1. Bio-distribution study of Reolysin® (pelareorep) through a single intravenous infusion in Sprague-Dawley rats.
Chakrabarty R; Tran H; Boulay I; Moran T; Parenteau A; Tavcar R; Bigras M; Hagerman A; Serl S; Thompson B; Coffey M
Invest New Drugs; 2013 Dec; 31(6):1476-86. PubMed ID: 24121993
[TBL] [Abstract][Full Text] [Related]
2. The oncolytic virus, pelareorep, as a novel anticancer agent: a review.
Chakrabarty R; Tran H; Selvaggi G; Hagerman A; Thompson B; Coffey M
Invest New Drugs; 2015 Jun; 33(3):761-74. PubMed ID: 25693885
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of REOLYSIN
Mahalingam D; Fountzilas C; Moseley J; Noronha N; Tran H; Chakrabarty R; Selvaggi G; Coffey M; Thompson B; Sarantopoulos J
Cancer Chemother Pharmacol; 2017 Apr; 79(4):697-703. PubMed ID: 28289863
[TBL] [Abstract][Full Text] [Related]
4. Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma.
Islam S; Espitia CM; Persky DO; Carew JS; Nawrocki ST
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372612
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of homogeneity and genetic stability of REOLYSIN (pelareorep) by complete genome sequencing of reovirus after large scale production.
Chakrabarty R; Tran H; Fortin Y; Yu Z; Shen SH; Kolman J; Onions D; Voyer R; Hagerman A; Serl S; Kamen A; Thompson B; Coffey M
Appl Microbiol Biotechnol; 2014 Feb; 98(4):1763-70. PubMed ID: 24419798
[TBL] [Abstract][Full Text] [Related]
6. Reovirus therapy in cancer: has the orphan virus found a home?
Yap TA; Brunetto A; Pandha H; Harrington K; Debono JS
Expert Opin Investig Drugs; 2008 Dec; 17(12):1925-35. PubMed ID: 19012507
[TBL] [Abstract][Full Text] [Related]
7. Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.
Bradbury PA; Morris DG; Nicholas G; Tu D; Tehfe M; Goffin JR; Shepherd FA; Gregg RW; Rothenstein J; Lee C; Kuruvilla S; Keith BD; Torri V; Blais N; Hao D; Korpanty GJ; Goss G; Melosky BL; Mates M; Leighl N; Ayoub JP; Sederias J; Feilotter H; Seymour L; Laurie SA
Lung Cancer; 2018 Jun; 120():142-148. PubMed ID: 29748010
[TBL] [Abstract][Full Text] [Related]
8. Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer.
Carew JS; Espitia CM; Zhao W; Kelly KR; Coffey M; Freeman JW; Nawrocki ST
Cell Death Dis; 2013 Jul; 4(7):e728. PubMed ID: 23868061
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in the Most Oncolytic Reovirus Strain Confer Enhanced Cell Attachment, Transcription, and Single-Step Replication Kinetics.
Mohamed A; Smiley JR; Shmulevitz M
J Virol; 2020 Jan; 94(4):. PubMed ID: 31776267
[TBL] [Abstract][Full Text] [Related]
10. The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors.
Kapadia R; Coffey MC
Methods; 2010 Dec; 52(4):301-6. PubMed ID: 20801221
[TBL] [Abstract][Full Text] [Related]
11. Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus.
Kelly KR; Espitia CM; Zhao W; Wendlandt E; Tricot G; Zhan F; Carew JS; Nawrocki ST
Oncotarget; 2015 Dec; 6(38):41275-89. PubMed ID: 26513296
[TBL] [Abstract][Full Text] [Related]
12. A Phase II Study of Pelareorep (REOLYSIN
Mahalingam D; Goel S; Aparo S; Patel Arora S; Noronha N; Tran H; Chakrabarty R; Selvaggi G; Gutierrez A; Coffey M; Nawrocki ST; Nuovo G; Mita MM
Cancers (Basel); 2018 May; 10(6):. PubMed ID: 29799479
[TBL] [Abstract][Full Text] [Related]
13. Reovirus: Rationale and clinical trial update.
Lal R; Harris D; Postel-Vinay S; de Bono J
Curr Opin Mol Ther; 2009 Oct; 11(5):532-9. PubMed ID: 19806501
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas.
Carew JS; Espitia CM; Zhao W; Mita MM; Mita AC; Nawrocki ST
Oncotarget; 2017 Oct; 8(49):86769-86783. PubMed ID: 29156834
[TBL] [Abstract][Full Text] [Related]
15. REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.
Morris DG; Feng X; DiFrancesco LM; Fonseca K; Forsyth PA; Paterson AH; Coffey MC; Thompson B
Invest New Drugs; 2013 Jun; 31(3):696-706. PubMed ID: 22886613
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Cohn DE; Sill MW; Walker JL; O'Malley D; Nagel CI; Rutledge TL; Bradley W; Richardson DL; Moxley KM; Aghajanian C
Gynecol Oncol; 2017 Sep; 146(3):477-483. PubMed ID: 28756871
[TBL] [Abstract][Full Text] [Related]
17. REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.
Comins C; Spicer J; Protheroe A; Roulstone V; Twigger K; White CM; Vile R; Melcher A; Coffey MC; Mettinger KL; Nuovo G; Cohn DE; Phelps M; Harrington KJ; Pandha HS
Clin Cancer Res; 2010 Nov; 16(22):5564-72. PubMed ID: 20926400
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.
Sborov DW; Nuovo GJ; Stiff A; Mace T; Lesinski GB; Benson DM; Efebera YA; Rosko AE; Pichiorri F; Grever MR; Hofmeister CC
Clin Cancer Res; 2014 Dec; 20(23):5946-55. PubMed ID: 25294913
[TBL] [Abstract][Full Text] [Related]
19. Reovirus-based therapy for cancer.
Kelly K; Nawrocki S; Mita A; Coffey M; Giles FJ; Mita M
Expert Opin Biol Ther; 2009 Jul; 9(7):817-30. PubMed ID: 19527106
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.
Kolb EA; Sampson V; Stabley D; Walter A; Sol-Church K; Cripe T; Hingorani P; Ahern CH; Weigel BJ; Zwiebel J; Blaney SM
Pediatr Blood Cancer; 2015 May; 62(5):751-8. PubMed ID: 25728527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]